Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(7):939–942. doi: 10.1038/bjc.1997.488

Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer.

T Kylmälä 1, T Taube 1, T L Tammela 1, L Risteli 1, J Risteli 1, I Elomaa 1
PMCID: PMC2228066  PMID: 9328156

Abstract

Fifty-seven patients with advanced prostate cancer resistant to first-line hormonal therapy were treated with estramustine and additionally randomized for treatment with clodronate or placebo. Clodronate treatment was started with 5 days intravenous administration (300 mg day[-1]) and followed by oral treatment (1.6 g day[-1]) for 12 months. Skeletal pain relief was only about 10% better in the clodronate than in the placebo group. The results do not support the superiority of combined intravenous and oral treatment with clodronate compared with oral administration only.

Full text

PDF
939

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami S., Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res. 1989;116:67–72. doi: 10.1007/978-3-642-83668-8_6. [DOI] [PubMed] [Google Scholar]
  2. Adami S., Salvagno G., Guarrera G., Bianchi G., Dorizzi R., Rosini S., Mobilio G., Lo Cascio V. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol. 1985 Dec;134(6):1152–1154. doi: 10.1016/s0022-5347(17)47663-4. [DOI] [PubMed] [Google Scholar]
  3. Cresswell S. M., English P. J., Hall R. R., Roberts J. T., Marsh M. M. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol. 1995 Sep;76(3):360–365. doi: 10.1111/j.1464-410x.1995.tb07715.x. [DOI] [PubMed] [Google Scholar]
  4. Elomaa I., Kylmälä T., Tammela T., Viitanen J., Ottelin J., Ruutu M., Jauhiainen K., Ala-Opas M., Roos L., Seppänen J. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol. 1992;24(2):159–166. doi: 10.1007/BF02549644. [DOI] [PubMed] [Google Scholar]
  5. Kylmälä T., Tammela T. L., Lindholm T. S., Seppänen J. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chir Gynaecol. 1994;83(4):316–319. [PubMed] [Google Scholar]
  6. Kylmälä T., Tammela T., Risteli L., Risteli J., Taube T., Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer. 1993;29A(6):821–825. doi: 10.1016/s0959-8049(05)80417-4. [DOI] [PubMed] [Google Scholar]
  7. Melkko J., Niemi S., Risteli L., Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 1990 Jul;36(7):1328–1332. [PubMed] [Google Scholar]
  8. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993 Apr;39(4):635–640. [PubMed] [Google Scholar]
  9. Robertson A. G., Reed N. S., Ralston S. H. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol. 1995 Sep;13(9):2427–2430. doi: 10.1200/JCO.1995.13.9.2427. [DOI] [PubMed] [Google Scholar]
  10. Schmidt J. D., Gibbons R. P., Johnson D. E., Prout G. R., Scott W. W., Murphy G. P. Chemotherapy of advanced prostatic cancer. Evaluation of response parameters. Urology. 1976 Jun;7(6):602–610. doi: 10.1016/0090-4295(76)90085-6. [DOI] [PubMed] [Google Scholar]
  11. Soloway M. S., Hardeman S. W., Hickey D., Raymond J., Todd B., Soloway S., Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988 Jan 1;61(1):195–202. doi: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  12. Taube T., Kylmälä T., Lamberg-Allardt C., Tammela T. L., Elomaa I. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study. Eur J Cancer. 1994;30A(6):751–758. doi: 10.1016/0959-8049(94)90287-9. [DOI] [PubMed] [Google Scholar]
  13. Vorreuther R. Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol. 1993 Nov;72(5 Pt 2):792–795. doi: 10.1111/j.1464-410x.1993.tb16269.x. [DOI] [PubMed] [Google Scholar]
  14. Vorreuther R., Klotz T., Engelking R. Clodronat in der palliativen Therapie des ossär metastasierten Prostatakarzinoms. Urologe A. 1992 Mar;31(2):63–66. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES